Truist Securities Reiterates Buy on Corcept Therapeutics, Raises Price Target to $65
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has reiterated its Buy rating on Corcept Therapeutics and raised the price target from $44 to $65.
June 04, 2024 | 1:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities has reiterated its Buy rating on Corcept Therapeutics and raised the price target from $44 to $65.
The reiteration of a Buy rating and a significant increase in the price target from $44 to $65 by Truist Securities is likely to positively impact the stock price of Corcept Therapeutics in the short term. This indicates strong confidence from the analyst in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100